These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37939733)

  • 1. Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of Life.
    Niu S; Li Y; Shao H; Hu J; Wang J; Wang H; Zhang Y
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):770-780. PubMed ID: 37939733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
    Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
    Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of skin toxicity in patients with extranodal nasal-type natural killer/T-cell lymphoma after treatment with intensity-modulated radiotherapy and conventional radiotherapy.
    Gu Y; Yu H; Zuo X; Cao Q; Liang T; Ren Y; Yang H; Yang D
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S975-S979. PubMed ID: 30539832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

  • 6. The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma.
    Song Y; Li J; Wang S; Zhou Z; Qiao X; Zhao X
    Leuk Lymphoma; 2021 Dec; 62(12):2907-2914. PubMed ID: 34261418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
    Qi F; Wang WH; He XH; Chen B; Gui L; Fang H; Liu P; Wang SL; Yang JL; Song YW; Yang S; Qi SN; Zhou SY; Li YX; Dong M
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):61-70. PubMed ID: 30102205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer.
    Jiang Y; Wang J; Jiang P; Wang X; Zhang L; Zhang Y
    BMC Cancer; 2023 May; 23(1):481. PubMed ID: 37245053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
    Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
    Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation.
    Lee N; Xia P; Fischbein NJ; Akazawa P; Akazawa C; Quivey JM
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):49-60. PubMed ID: 12909215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma.
    Yang Y; Cao JZ; Lan SM; Wu JX; Wu T; Zhu SY; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Xu LM; Yuan ZY; Qi SN; Li YX
    JAMA Oncol; 2017 Jan; 3(1):83-91. PubMed ID: 27893001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.
    Shen Q; Ma X; Hu W; Chen L; Huang J; Guo Y
    Radiat Oncol; 2013 Jun; 8():152. PubMed ID: 23800149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gross tumor volume and radiation dose on survival and locoregional recurrence in early-stage extranodal NK/T-cell lymphoma treated with intensity-modulated radiation therapy.
    Zhou YM; Liu X; Yang Y; Wang SL; Fang H; Song YW; Liu YP; Jin J; Li N; Lu NN; Jing H; Tang Y; Chen B; Zhang WW; Zhai YR; Men K; Dai JR; Deng M; Qi SN; Li YX
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5219-5230. PubMed ID: 36374333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of volumetric modulated arc therapy and sliding-window intensity-modulated radiotherapy in the treatment of Stage I-II nasal natural killer/T-cell lymphoma.
    Liu X; Yang Y; Jin F; He Y; Zhong M; Luo H; Qiu D; Li C; Yang H; He G; Wang Y
    Med Dosim; 2016; 41(1):42-6. PubMed ID: 26428072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphoma.
    Tomita N; Kodaira T; Tachibana H; Nakamura T; Nakahara R; Inokuchi H; Mizoguchi N; Takada A
    Br J Radiol; 2009 Aug; 82(981):756-63. PubMed ID: 19366734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.
    Sultanem K; Shu HK; Xia P; Akazawa C; Quivey JM; Verhey LJ; Fu KK
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):711-22. PubMed ID: 11020568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.